Asahi Kasei Pharma, research support for drug discovery research and technology: Open Innovation 2023

New York and Düsseldorf, Germany and Tokyo–(business wire)– Asahi Kasei Pharma, a subsidiary of the diversifying Japanese multinational corporation Asahi Kasei, has announced the We are soliciting new proposals for drug development research. In the world. The application period begins on January 5, 2023 at 5:00 AM GMT and ends on February 28, 2023 at 8:00 AM GMT.

Asahi Kasei Pharma established its Open Innovation Division in October 2016 with the mission to further enhance and strengthen its global licensing and alliance building activities, and has since funded an average of approximately five proposals annually. In total, we have funded more than 20 state state proposals. – A rich collection of creative new ideas as well as cutting-edge drug development. The Open Innovation team is looking to fund innovative proposals from researchers around the world with up to US$200,000 annually for each project in this round, scheduled for 2023. Asahi Kasei Pharma will then pursue collaborative research opportunities with drug discovery researchers and their parents. Institutions wishing to create new innovative drugs for diseases with currently unmet needs or to pioneer new platform technologies for drug discovery.

Asahi Kasei Pharma has a track record of successful drug development in the areas of autoimmune, renal, neurological and bone diseases, and is able to provide the greatest contribution from related research areas and subjects.

“Asahi Kasei Pharma believes that illness should not stop people from doing what they want to do.We believe that great science comes from working together, and we are excited about the opportunity to work with researchers around the world to accomplish this mission. ”

Open innovation is committed to establishing research collaborations related to innovative drug discovery targets and candidate drug compounds up to the preclinical stage, as well as advanced drug discovery technologies. Advances in searching for new mechanisms of action to treat intractable autoimmune diseases have been one of the most promising achievements of research to date, with more to come. Asahi Kasei believes that continuous efforts to advance drug discovery and research technology will make a further contribution to the lives and livelihoods of people around the world.

Recruitment overview

Target audience:

Researchers at overseas universities, research institutes, and companies

(For researchers residing in Japan, please refer to the Japanese site.)

Research fields and subjects:

1. Autoimmune diseases – new drug candidates and new drug development technologies

2. New drug candidates for renal disease and new drug development technology

3. Pain and Neurodegenerative Diseases – New Drug Candidates and New Drug Development Technologies

4. Bone disease – candidate drug

5. Fundamental Technology for Drug Discovery – Formulation, Analysis Method, Organic Synthesis –

Funding:

Up to $200,000 per year per selected proposal

Research period:

1 to 3 years (Milestones are set every year, and research content is reviewed as appropriate based on research results.)

Entries will be judged for their potential as concepts for joint research and research development. For more information, please visit Asahi Kasei Pharma’s open innovation website.

About Asahi Kasei Pharma

In line with its mission,Asahi Kasei Pharma operates the pharmaceuticals and diagnostics business in the healthcare sector of the Asahi Kasei Group. Asahi Kasei Pharma has developed a number of innovative medicines in the areas of rare diseases such as immunology, neurology, critical care, and musculoskeletal disorders, providing highly innovative medicines to patients suffering from previously unmet diseases. We have contributed to society by providing pharmaceuticals.

For more information, please visit https://www.asahikasei-pharma.co.jp/en/.

About Asahi Kasei

The Asahi Kasei Group contributes to the lives of people around the world. Since its founding in 1922 as an ammonia and cellulose fiber business, Asahi Kasei has continued to grow through aggressive transformation of its business portfolio in order to meet the changing needs of the times. With more than 46,000 employees worldwide, he contributes to a sustainable society by providing solutions to global challenges through his three business divisions: Materials, Homes and Healthcare. . The Company’s healthcare business includes devices and systems for critical care, dialysis, therapeutic apheresis, blood transfusion, biotherapeutic manufacturing, pharmaceuticals and diagnostic reagents. Please see https://www.asahi-kasei.com/ for details.

Asahi Kasei is also committed to sustainability initiatives, contributing to the realization of a carbon-neutral society by 2050. For more information, please visit https://www.asahi-kasei.com/sustainability/.